Greywolf Therapeutics

Greywolf Therapeutics is advancing novel antigen modulation technology to guide the immune system.​​​ ​Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. ​ We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. ​ This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.

Unlocking a new therapeutic branch ​

We are the first to explore the untapped potential of changing Signal 1, despite its fundamental importance in T cell activation. 

T-cell activation requires a chain of three signals: antigen recognition (1), co-stimulation (2), and cytokine-mediated differentiation and expansion (3).​

Robust clinical data ​

Our lead antigen modulator (GRWD5769) is delivering promising results during Phase 1/2 trial in oncology, demonstrating proof of mechanism and target engagement. ​Our next (GRWD0715) is progressing in a Phase 1/2 trial as a treatment for the autoimmune disorder axial spondyloarthritis.

Backed for success​

We have raised $131M from top venture capital funds.​

Our founders are Peter Joyce, former R&D Lead at Vertex Pharmaceuticals, and Tom McCarthy, former President and CEO of Spinifex Pharmaceuticals (acquired by Novartis for ~$700M).

• Small molecules
• Immunology/inflammation
• Platform Technology
• Oncology
• Translational Medicine
• Enzyme
• Biomarkers